







正 誤 表 ERRATA
薬 学 雜 誌 YAKUGAKU ZASSHI

卷 Vol.	頁 Page	行 Line	誤 Error	正 Correction																																																		
128	972	Fig. 1-2. structure	II. Phenethylamines  <table border="1" style="width: 100%; text-align: center;"> <thead> <tr> <th>R₁</th> <th>R₂</th> <th>R₃</th> <th>R₄</th> <th>Compounds</th> </tr> </thead> <tbody> <tr> <td>OCH₃</td> <td>H</td> <td>CH₃</td> <td>H</td> <td>1-(2-Methoxy-4,5-methylenedioxyphenyl)propan-2-amine (MMDA-2)</td> </tr> <tr> <td>H</td> <td>H</td> <td>CH₂CH₃</td> <td>H</td> <td>1-(3,4-Methylenedioxyphenyl)butan-2-amine (BDB)</td> </tr> <tr> <td>H</td> <td>-O</td> <td>CH₂CH₃</td> <td>CH₃</td> <td>2-Methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (bk-MBDB)*</td> </tr> <tr> <td>H</td> <td>-O</td> <td>CH₃</td> <td>CH₂CH₃</td> <td>2-Ethylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (Ethylone, bk-MDEA)*</td> </tr> </tbody> </table>	R ₁	R ₂	R ₃	R ₄	Compounds	OCH ₃	H	CH ₃	H	1-(2-Methoxy-4,5-methylenedioxyphenyl)propan-2-amine (MMDA-2)	H	H	CH ₂ CH ₃	H	1-(3,4-Methylenedioxyphenyl)butan-2-amine (BDB)	H	-O	CH ₂ CH ₃	CH ₃	2-Methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (bk-MBDB)*	H	-O	CH ₃	CH ₂ CH ₃	2-Ethylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (Ethylone, bk-MDEA)*	II. Phenethylamines  <table border="1" style="width: 100%; text-align: center;"> <thead> <tr> <th>R₁</th> <th>R₂</th> <th>R₃</th> <th>R₄</th> <th>Compounds</th> </tr> </thead> <tbody> <tr> <td>OCH₃</td> <td>H</td> <td>CH₃</td> <td>H</td> <td>1-(2-Methoxy-4,5-methylenedioxyphenyl)propan-2-amine (MMDA-2)</td> </tr> <tr> <td>H</td> <td>H</td> <td>CH₂CH₃</td> <td>H</td> <td>1-(3,4-Methylenedioxyphenyl)butan-2-amine (BDB)</td> </tr> <tr> <td>H</td> <td>-O</td> <td>CH₂CH₃</td> <td>CH₃</td> <td>2-Methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (bk-MBDB)*</td> </tr> <tr> <td>H</td> <td>-O</td> <td>CH₃</td> <td>CH₂CH₃</td> <td>2-Ethylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (Ethylone, bk-MDEA)*</td> </tr> </tbody> </table>	R ₁	R ₂	R ₃	R ₄	Compounds	OCH ₃	H	CH ₃	H	1-(2-Methoxy-4,5-methylenedioxyphenyl)propan-2-amine (MMDA-2)	H	H	CH ₂ CH ₃	H	1-(3,4-Methylenedioxyphenyl)butan-2-amine (BDB)	H	-O	CH ₂ CH ₃	CH ₃	2-Methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (bk-MBDB)*	H	-O	CH ₃	CH ₂ CH ₃	2-Ethylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (Ethylone, bk-MDEA)*
			R ₁	R ₂	R ₃	R ₄	Compounds																																															
			OCH ₃	H	CH ₃	H	1-(2-Methoxy-4,5-methylenedioxyphenyl)propan-2-amine (MMDA-2)																																															
			H	H	CH ₂ CH ₃	H	1-(3,4-Methylenedioxyphenyl)butan-2-amine (BDB)																																															
H	-O	CH ₂ CH ₃	CH ₃	2-Methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (bk-MBDB)*																																																		
H	-O	CH ₃	CH ₂ CH ₃	2-Ethylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (Ethylone, bk-MDEA)*																																																		
R ₁	R ₂	R ₃	R ₄	Compounds																																																		
OCH ₃	H	CH ₃	H	1-(2-Methoxy-4,5-methylenedioxyphenyl)propan-2-amine (MMDA-2)																																																		
H	H	CH ₂ CH ₃	H	1-(3,4-Methylenedioxyphenyl)butan-2-amine (BDB)																																																		
H	-O	CH ₂ CH ₃	CH ₃	2-Methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (bk-MBDB)*																																																		
H	-O	CH ₃	CH ₂ CH ₃	2-Ethylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (Ethylone, bk-MDEA)*																																																		
			 <p style="text-align: center;">N-Methyl-4-(3,4-methylenedioxyphenyl)butan-2-amine (HMDMA)</p>	 <p style="text-align: center;">N-Methyl-4-(3,4-methylenedioxyphenyl)butan-2-amine (HMDMA)</p>																																																		
	973	Fig. 1-3. structure	III. Piperazines  <p style="text-align: center;">1-(3,4-Methylenedioxybenzyl)piperazine* (MDBP, piperonyl piperazine)</p>	III. Piperazines  <p style="text-align: center;">1-(3,4-Methylenedioxybenzyl)piperazine* (MDBP, piperonyl piperazine)</p>																																																		
No. 10 ii	下から 9行目		<p style="text-align: center;">—Notes—</p> Analysis of Designer Drugs Detected in the Products Purchased in Fiscal Year 2006 ……N. Uchiyama, R. Kikura-Hanajiri, N. Kawahara, and Y. Goda · 1499	<p style="text-align: center;">—Articles—</p> Analysis of Designer Drugs Detected in the Products Purchased in Fiscal Year 2006 ……N. Uchiyama, R. Kikura-Hanajiri, N. Kawahara, and Y. Goda · 1499																																																		
No. 10 iii	下から 8行目		<p style="text-align: center;">—ノ—ト—</p> 2006年度買い上げ違法ドラッグ製品から検出されたデザイナードラッグ成分のNMRを中心とした分析…内山奈穂子, 花尻(木倉)瑠理, 川原信夫, 合田幸広 · 1499	<p style="text-align: center;">—資—料—</p> 2006年度買い上げ違法ドラッグ製品から検出されたデザイナードラッグ成分のNMRを中心とした分析…内山奈穂子, 花尻(木倉)瑠理, 川原信夫, 合田幸広 · 1499																																																		
1559	脚注		本総説は、日本薬学会第128年会シンポジウム <u>GS3</u> で発表したものである。	本総説は、日本薬学会第128年会シンポジウム <u>S32</u> で発表したものである。																																																		